Oppenheimer analyst Jason Helfstein maintained a Buy rating on Trade Desk (TTD – Research Report) yesterday and set a price target of $115.00.

PolyPid Ltd., a late-stage biopharma company focused on enhancing surgical outcomes, announced that its management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference ...